您当前的位置：

Mofezolac

(Synonyms: 莫苯唑酸)

目录号: PL02471 纯度: ≥98%

Mofezolac，一种非甾体类抗炎药 (NSAID)，是一种选择性，可逆和具有口服活性的 COX-1 抑制剂，IC50 为 1.44 nM。Mofezolac 对 COX-2 的抑制活性较弱 (IC50 为 447 nM)。Mofezolac 可缓解疼痛并具有抗炎活性。

CAS No. :78967-07-4

商品编号	规格	价格	会员价
PL02471-5mg	5mg	¥342.00	请登录
PL02471-10mg	10mg	¥583.00	请登录
PL02471-25mg	25mg	¥1145.00	请登录
PL02471-50mg	50mg	¥1885.00	请登录
PL02471-100mg	100mg	¥2765.00	请登录
PL02471-200mg	200mg	询价	询价
PL02471-500mg	500mg	询价	询价
PL02471-10mM*1mLinDMSO	10mM*1mLinDMSO	¥1237.00	请登录
PL02471-1 mL x 10 mM (in DMSO)		¥378.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Mofezolac
中文别名	莫非佐酸;莫苯唑酸
英文名称	Mofezolac
英文别名	2-(3,4-Bis(4-methoxyphenyl)isoxazol-5-yl)acetic acid;[3,4-Bis-(4-methoxyphenyl)isoxazol-5-yl]-acetic acid;5-Isoxazoleacetic acid,3,4-bis(4-methoxyphenyl)-;MOFEZOLAC;[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]a;3,4-Bis((4-methoxyphenyl)-5-isooxazolyl)acetic acid;3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid;3,4-bis(p-Methoxyphenyl)-5-isoxazoleacetic acid;Acetic acid, 3,4-bis(4-methoxyphenyl)-5-isooxazolyl-;BRN 5986171;CCRIS 4316;Mofezolac [INN];Mofezolaco;Mofezolaco [INN-Spanish];Mofezolacum;Mofezolacum [INN-Latin];N-22;UNII-RVJ0BV3H3Y;N 22;Mofezolac (TN);5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)-;RVJ0BV3H3Y;C19H17NO5;(3,4-bis(4-methoxyphenyl)-5-isoxazolyl)acetic acid;[3,4-Bis-(4-me
Cas No.	78967-07-4
分子式	C₁₉H₁₇NO₅
分子量	339.34
包装储存	Powder -20°C 3 years；In solvent -80°C 6 months
详情描述	Mofezolac，一种非甾体类抗炎药 (NSAID)，是一种选择性，可逆和具有口服活性的 COX-1 抑制剂，IC50 为 1.44 nM。Mofezolac 对 COX-2 的抑制活性较弱 (IC50 为 447 nM)。Mofezolac 可缓解疼痛并具有抗炎活性。

产品详情	Mofezolac，一种非甾体类抗炎药 (NSAID)，是一种选择性，可逆和具有口服活性的 COX-1 抑制剂，IC₅₀ 为 1.44 nM。Mofezolac 对 COX-2 的抑制活性较弱 (IC₅₀ 为 447 nM)。Mofezolac 可缓解疼痛并具有抗炎活性。
生物活性	Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active COX-1 inhibitor with an IC 50 of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC 50 of 447 nM). Mofezolac can relieve pain and has anti-inflammatory activities.
性状	Solid
IC50 & Target[1][2]	COX-1 1.44 nM (IC50) COX-2 447 nM (IC
体外研究(In Vitro)	Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay. Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；In solvent -80°C 6 months
参考文献	[1]. K Goto, et al. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 1998 Jul;56(4):245-54. [2]. Maria Laura Pati, et al. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability. Eur J Med Chem. 2019 Feb 15;164:59-76.

溶解度数据	In Vitro: DMSO : 100 mg/mL (294.69 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. K Goto, et al. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 1998 Jul;56(4):245-54.
[2]. Maria Laura Pati, et al. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability. Eur J Med Chem. 2019 Feb 15;164:59-76.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Mofezolac

相关产品

The molarity calculator equation

The dilution calculator equation